JP2024521968A - 白内障手術を受ける患者において使用するための、シクロスポリン製剤 - Google Patents

白内障手術を受ける患者において使用するための、シクロスポリン製剤 Download PDF

Info

Publication number
JP2024521968A
JP2024521968A JP2023576353A JP2023576353A JP2024521968A JP 2024521968 A JP2024521968 A JP 2024521968A JP 2023576353 A JP2023576353 A JP 2023576353A JP 2023576353 A JP2023576353 A JP 2023576353A JP 2024521968 A JP2024521968 A JP 2024521968A
Authority
JP
Japan
Prior art keywords
weight
hco
formulation
cyclosporine
octoxynol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521968A5 (https=
Inventor
ホバネシアン，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2024521968A publication Critical patent/JP2024521968A/ja
Publication of JP2024521968A5 publication Critical patent/JP2024521968A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023576353A 2021-06-14 2022-06-13 白内障手術を受ける患者において使用するための、シクロスポリン製剤 Pending JP2024521968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202479P 2021-06-14 2021-06-14
US63/202,479 2021-06-14
PCT/IB2022/055462 WO2022264006A1 (en) 2021-06-14 2022-06-13 Cyclosporine formulations for use in patients undergoing cataract surgery

Publications (2)

Publication Number Publication Date
JP2024521968A true JP2024521968A (ja) 2024-06-04
JP2024521968A5 JP2024521968A5 (https=) 2025-07-31

Family

ID=82321536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576353A Pending JP2024521968A (ja) 2021-06-14 2022-06-13 白内障手術を受ける患者において使用するための、シクロスポリン製剤

Country Status (5)

Country Link
US (1) US20250009837A1 (https=)
EP (1) EP4355301A1 (https=)
JP (1) JP2024521968A (https=)
AU (1) AU2022295164A1 (https=)
WO (1) WO2022264006A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747455C2 (ru) * 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
WO2025163677A1 (en) * 2024-01-31 2025-08-07 Registrar, Panjab University, Chandigarh Nanomicellar composition for high permeation and extended-release drug delivery system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009144186A (ru) * 2007-05-04 2011-06-10 Аллерган, Инк. (Us) Применение циклоспоринов при лечении пациентов с интраокулярными линзами
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения

Also Published As

Publication number Publication date
AU2022295164A1 (en) 2024-01-25
EP4355301A1 (en) 2024-04-24
US20250009837A1 (en) 2025-01-09
WO2022264006A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
US12569452B2 (en) Ophthalmic compositions comprising F6H8
Almeida et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery
AU2020266339B2 (en) Dissolvable polymeric eye inserts and method of using same
CN115066232B (zh) 用于治疗眼病的组合物和方法
JP2022505950A (ja) 老眼、散瞳、および他の眼障害の治療のための方法および組成物
JP6994061B2 (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CA3113462A1 (en) Formulations of reproxalap for the treatment of dry eye disease
JP2012528888A (ja) 眼科用配合剤、その製造方法およびその使用方法
BR112020021845A2 (pt) tratamentos para presbiopia
US20250009837A1 (en) Cyclosporine formulations for use in patients undergoing cataract surgery
JP2022508715A (ja) 緑内障および関連状態の処置のための方法および組成物
CN115697333A (zh) 包含阿西替尼的组合物和治疗眼部疾病的方法
Eaton et al. Effects of topically applied heterologous serum on reepithelialization rate of superficial chronic corneal epithelial defects in dogs
Hoehn et al. Comparison of ultrasonic pachymetry and Fourier-domain optical coherence tomography for measurement of corneal thickness in dogs with and without corneal disease
US20230372236A1 (en) Drug containing dissolvable ocular inserts and method of using same
WO2023072163A1 (en) Methods of using cyclosporine a ophthalmic gel in treating moderate-to-severe dry eye disease
Cruz et al. Postoperative safety outcomes in patients undergoing routine phacoemulsification cataract surgery with intraoperative intracameral injection of preservative-free moxifloxacin versus levofloxacin
Kumar et al. Efficacy and Adverse Effects of Topical Latanoprost with Respect to Preservative in Patients of POAG.
Zhang et al. Comparison study between pilocarpine and tropicamide drops on corneal topography and their effect on IL-6 and TNF-α levels in tear
US20260083720A1 (en) Childhood Atropine For Myopia Progression
Omar et al. Corneal topographic changes after two different grafting pterygium surgery techniques
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
Michaud et al. Measurement of the Retention Time of Two Different Carbomer‐Based Ophthalmic Gels With and Without Hyaluronic Acid in Anesthetized Dogs Using Ultrahigh‐Resolution Optical Coherence Tomography
CA3076567C (en) Ophthalmic compositions comprising f6h8
JAIN et al. Efficacy of 0.1% Topical Nepafenac in Maintaining Transoperative Mydriasis and Preventing Postoperative Macular Oedema in Phacoemulsification Cataract Surgery: A Research Protocol.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723